Pomerantz LLP Opens Investigation Into Medline Industries (NASDAQ: MDLN) on Behalf of Investors

Pomerantz LLP has launched an investigation into Medline Industries, Inc. (NASDAQ: MDLN) on behalf of the company's investors, the New York-based law firm announced on June 18, 2026. The firm is urging affected investors to make contact as it works to assess potential claims.

Investigation Underway at Pomerantz LLP

Pomerantz LLP, which operates out of New York, disclosed that it is actively investigating claims connected to Medline Industries, a company listed on the Nasdaq exchange under the ticker MDLN. The firm did not specify in its announcement the precise nature of the alleged wrongdoing or the time period under review. No monetary figures, settlement targets, or lawsuit filings were referenced in the initial disclosure.

Investor alert notices of this type from plaintiff-side law firms typically signal an early-stage inquiry into potential securities violations, though no formal complaint has been cited in the source materials.

How Investors Can Participate

Pomerantz LLP has directed investors who hold or held shares of Medline Industries to contact the firm directly. The designated point of contact is Danielle Peyton, who can be reached at [email protected] or by phone at 646-581-9980, extension 7980.

Law firms conducting these investigations commonly seek investors who may have suffered losses to help establish standing for potential class action proceedings. Participation at this stage carries no obligation.

What Investors Should Know

Medline Industries trades on the Nasdaq under the symbol MDLN. The source materials contain no details on current share price, market capitalization, or the specific conduct at the center of Pomerantz LLP's inquiry. Investors seeking additional context should monitor further filings and disclosures from both the company and the law firm.

Given the limited detail available at this stage, market participants with exposure to MDLN may wish to consult independent legal counsel and track any forthcoming statements from Medline Industries' management regarding the investigation.